AbbVie (ABBV)
(Delayed Data from NYSE)
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.
Zacks Investment Ideas feature highlights: Dollar Tree, AbbVie and Sysco
by Zacks Equity Research
Dollar Tree, AbbVie and Sysco are part of Zacks Investment Ideas article.
3 Recession-Proof Stocks Up 10% in 2022 to Buy Right Now
by Benjamin Rains
Today, we dive into three stocks that are poised to beat inflation and rise above any possible recession. All three names appear worth buying for the second half of 2022 and might be up for consideration as buy-and-hold stocks...
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Top Analyst Reports for Pfizer, Raytheon Technologies & Diageo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Raytheon Technologies Corporation (RTX), and Diageo plc (DEO).
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $153.23, moving +0.25% from the previous trading session.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why
by Zacks Equity Research
Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropathy indication.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $153.93, moving +0.08% from the previous trading session.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $153.14, marking a +0.53% move from the previous day.
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication
by Zacks Equity Research
The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
by Kinjel Shah
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
by Zacks Equity Research
With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $138.28 in the latest trading session, marking a -0.63% move from the prior day.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
by Zacks Equity Research
The FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was supported by data from two phase III induction studies - ADVANCE, MOTIVATE, and one maintenance study - FORTIFY.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $137.62 in the latest trading session, marking a -1.29% move from the prior day.
Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata
by Zacks Equity Research
Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.
The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T
by Zacks Equity Research
Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T have been included in this Analyst Blog.
Top Analyst Reports for Berkshire Hathaway, AbbVie & TotalEnergies
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. (ABBV), and TotalEnergies SE (TTE).
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH